4 results match your criteria: "Intermountain Medical Center Department of Medicine[Affiliation]"
Methods of a cluster-randomized, type II hybrid implementation effectiveness trial to prospectively assess extended-duration thromboprophylaxis for at-risk medical patients being discharged to prevent hospital-associated venous thromboembolism.
Res Pract Thromb Haemost
August 2024
Intermountain Medical Center Department of Medicine, Intermountain Health, Salt Lake City, Utah, USA.
Article Synopsis
- Venous thromboembolism (VTE) is a significant cause of preventable hospital deaths, especially in medically ill patients, with the risk of symptomatic VTE doubling after discharge.
- The eVTE trial aims to implement a system that alerts at-risk patients about postdischarge thromboprophylaxis, specifically using rivaroxaban, in a 23-hospital healthcare network.
- This study will assess the prescription rates, alongside efficacy and safety outcomes related to VTE, heart attacks, strokes, and major bleeding, using a framework for effective implementation and reporting.
D-dimer Thresholds to Exclude Pulmonary Embolism among COVID-19 Patients in the Emergency Department: Derivation with Independent Validation.
Clin Appl Thromb Hemost
August 2022
Department of Emergency Medicine, 12267Wayne State University School of Medicine, Detroit, MI, USA.
Objective: To derive and validate a D-dimer cutoff for ruling out pulmonary embolism (PE) in COVID-19 patients presenting to the emergency department (ED).
Methods: A retrospective cohort study was performed in an integrated healthcare system including 22 adult ED's between March 1, 2020, and January 31, 2021. Results were validated among patients enrolled in the RECOVER Registry, representing data from 154 ED's from 26 US states.
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications.
Pulm Circ
January 2019
10 Division of Human Genetics, Cincinnati Children's Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Diagnostic World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) and Diagnostic Group 1' pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) are progressive and fatal disorders. Past registries provided important insights into these disorders, but did not include hormonal exposures or genomic data. The United States Pulmonary Hypertension Scientific Registry (USPHSR) will provide demographic, physiologic, anorexigen and hormone exposure, genomic, and survival data in the current therapeutic era for 499 patients diagnosed with PAH, PVOD, or PCH.
View Article and Find Full Text PDF